# LEAP-008 (NCT03976375)

> Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab; lenvatinib
- Indication: metastatic NSCLC after platinum chemotherapy and immunotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03976375
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Non-Small Cell Lung Cancer
- Interventions: Pembrolizumab; Lenvatinib; Docetaxel
- Enrollment: 422
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

## Indexed commentary on LEAP-008 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- Podcasts: 5

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=leap-008-nct03976375

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03976375", "email": "<work email>"}; the inbox owner confirms by the emailed link.